IL74823A - Stable composition of interleukin-2 - Google Patents

Stable composition of interleukin-2

Info

Publication number
IL74823A
IL74823A IL74823A IL7482385A IL74823A IL 74823 A IL74823 A IL 74823A IL 74823 A IL74823 A IL 74823A IL 7482385 A IL7482385 A IL 7482385A IL 74823 A IL74823 A IL 74823A
Authority
IL
Israel
Prior art keywords
interleukin
stable composition
stable
composition
Prior art date
Application number
IL74823A
Other languages
English (en)
Other versions
IL74823A0 (en
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP59071568A external-priority patent/JPS60215631A/ja
Priority claimed from JP60013226A external-priority patent/JPS60222424A/ja
Priority claimed from JP60037184A external-priority patent/JPS61197527A/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of IL74823A0 publication Critical patent/IL74823A0/xx
Publication of IL74823A publication Critical patent/IL74823A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL74823A 1984-04-09 1985-04-04 Stable composition of interleukin-2 IL74823A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP59071568A JPS60215631A (ja) 1984-04-09 1984-04-09 インタ−ロイキン−２組成物
JP60013226A JPS60222424A (ja) 1985-01-25 1985-01-25 インタ−ロイキン−２組成物
JP60037184A JPS61197527A (ja) 1985-02-25 1985-02-25 インタ−ロイキン−２組成物

Publications (2)

Publication Number Publication Date
IL74823A0 IL74823A0 (en) 1985-07-31
IL74823A true IL74823A (en) 1989-07-31

Family

ID=27280163

Family Applications (1)

Application Number Title Priority Date Filing Date
IL74823A IL74823A (en) 1984-04-09 1985-04-04 Stable composition of interleukin-2

Country Status (13)

Country Link
US (2) US4645830A (fr)
EP (1) EP0158487B1 (fr)
KR (1) KR920005048B1 (fr)
AU (1) AU579359B2 (fr)
CA (1) CA1285478C (fr)
DE (1) DE3583880D1 (fr)
DK (1) DK148885A (fr)
ES (1) ES8603271A1 (fr)
IE (1) IE58161B1 (fr)
IL (1) IL74823A (fr)
NZ (1) NZ211702A (fr)
PH (1) PH22897A (fr)
PT (1) PT80247B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US5702699A (en) * 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158487B1 (fr) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Composition stable d'interleukine-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
CA1290249C (fr) * 1986-04-09 1991-10-08 Cetus Corporation TRAITEMENT A BASE D'INTERLEUKINE-2 ET (OU) D'INTERFERON .beta. ET FACTEUR DE NECROSE TUMORALE
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
EP0279846A1 (fr) * 1986-09-04 1988-08-31 Cetus Corporation Interleukine-2 succinylee pour compositions pharmaceutiques
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
CA1292686C (fr) * 1986-10-27 1991-12-03 Ze'ev Shaked Compositions pharmaceutiques d'interleukine-2 recombinante et procede de fabrication
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4938956A (en) * 1987-04-01 1990-07-03 International Minerals & Chemical Corp. Synergistic immunostimulating composition and method
CA1339757C (fr) 1987-04-16 1998-03-17 Robert F. Halenbeck Methode de production bacteriologique de csf-1 humain recombinant biologiquement actif pur
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US5417970A (en) * 1988-10-21 1995-05-23 Sanofi Drugs containing a glycosylated interleukin-2
FR2639232A1 (fr) * 1988-10-21 1990-05-25 Sanofi Sa Medicaments contenant une interleukine-2 glycosylee
DE68916237T2 (de) * 1988-12-06 1994-11-10 Otsuka Pharma Co Ltd Stabilisierte interleukin-1-beta enthaltende zusammensetzung.
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE68912582T2 (de) * 1989-01-09 1994-08-11 Meiji Milk Prod Co Ltd Anti-hiv-mittel.
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
CA1339256C (fr) * 1989-01-26 1997-08-12 Wulf Droge Traitement de maladies associees aux infections par le vih
US5140010A (en) * 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
IT1240314B (it) * 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
WO1992009623A1 (fr) * 1990-11-23 1992-06-11 Roussel-Uclaf PROCEDE DE PREPARATION D'UNE PROTEINE COMPORTANT AU MOINS UN PONT DISULFURE INTRAMOLECULAIRE PAR OXYDATION, A UN pH INFERIEUR A 5,0, DE LA PROTEINE RECOMBINANTE REDUITE CORRESPONDANTE
DE59109176D1 (de) * 1991-03-19 2000-02-17 Huntsman International Trading Verfahren zur Herstellung von geschäumten Massen auf Basis von Polyharnstoffelastomeren
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
WO1995002411A1 (fr) * 1993-07-16 1995-01-26 Mallinckrodt Veterinary Limited Formulation de facteur de croissance polypeptidique stabilisee a ph faible
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
WO1999055310A1 (fr) 1998-04-27 1999-11-04 Altus Biologics Inc. Cristaux de proteines stabilisees, formulations renfermant lesdits cristaux et leurs procedes de fabrication
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
AU4314900A (en) * 1999-04-28 2000-11-17 Yamanouchi Pharmaceutical Co., Ltd. Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
WO2001024814A1 (fr) 1999-10-04 2001-04-12 Chiron Corporation Compositions pharmaceutiques liquides stabilisees contenant un polypeptide
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
EP1232174B1 (fr) 1999-11-18 2013-05-01 Ischemix, Inc Compositions et methodes permettant de contrer les effets d'especes reagissant a l'oxygene et des radicaux libres
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
CA2447292A1 (fr) * 2001-05-17 2002-11-21 Ceremedix, Inc. Composes de peptides contrecarrant lessubstances oxygenees et les radicaux libres
DE10159245A1 (de) * 2001-12-03 2003-06-18 Degussa Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
JP2006515882A (ja) 2003-01-08 2006-06-08 カイロン コーポレイション 組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物
PL2040689T3 (pl) * 2006-06-22 2011-04-29 Gambro Lundia Ab Roztwór zawierający N-acetylocysteinę i kwas glukonowy oraz sposoby redukowania, leczenia i zapobiegania stresowi oksydacyjnemu i aktywacji komórek
JP2013525406A (ja) 2010-04-27 2013-06-20 スキル テクノロジー ゲーエムベーハー 安定ｍｉａ／ｃｄ−ｒａｐ製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AU2014314053C1 (en) 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
CN106659785B (zh) 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
JP7495426B2 (ja) 2019-03-14 2024-06-04 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥容器用充填治具、システム及び使用方法
AU2021207901A1 (en) 2020-01-14 2022-09-08 Synthekine, Inc. IL2 orthologs and methods of use
CA3226163A1 (fr) 2021-07-14 2023-01-19 Synthekine, Inc. Methodes et compositions destinees a etre utilisees dans la therapie cellulaire contre la maladie neoplasique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4404280A (en) * 1981-07-16 1983-09-13 Steven Gillis Process for preparing murine interleukin 2 in the presence of interleukin 1 from an interleukin 2 nonproducer malignant cell line and cell line therefor
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
US4447355A (en) * 1982-04-07 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158487B1 (fr) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Composition stable d'interleukine-2
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins

Also Published As

Publication number Publication date
KR850007378A (ko) 1985-12-04
IE58161B1 (en) 1993-07-28
DK148885A (da) 1985-10-10
AU579359B2 (en) 1988-11-24
US4812557A (en) 1989-03-14
PH22897A (en) 1989-01-19
PT80247A (en) 1985-05-01
PT80247B (pt) 1987-10-20
IE850902L (en) 1985-10-09
EP0158487A2 (fr) 1985-10-16
DE3583880D1 (de) 1991-10-02
CA1285478C (fr) 1991-07-02
DK148885D0 (da) 1985-04-02
IL74823A0 (en) 1985-07-31
NZ211702A (en) 1988-11-29
EP0158487A3 (en) 1987-08-19
US4645830A (en) 1987-02-24
ES542028A0 (es) 1985-12-16
ES8603271A1 (es) 1985-12-16
EP0158487B1 (fr) 1991-08-28
AU4083985A (en) 1985-10-17
KR920005048B1 (ko) 1992-06-26

Similar Documents

Publication Publication Date Title
IL74823A (en) Stable composition of interleukin-2
PH22531A (en) Stable composition of interferon
GB8420543D0 (en) Compositions of matter
ZA852302B (en) Stable composition of interleukin-2
GB8526735D0 (en) Compositions of matter
GB8521455D0 (en) Stable compositions of anthralin
ZA85497B (en) Stable composition of ypsilon-interferon
IL74093A0 (en) Stable composition of gamma-interferon
GB8429545D0 (en) Compositions of matter
GB8422918D0 (en) Compositions of matter
GB8422916D0 (en) Compositions of matter
GB8407861D0 (en) Manufacture of components
GB8512344D0 (en) Compositions of matter
GB8422917D0 (en) Compositions of matter
GB8406393D0 (en) Compositions of matter
GB8427438D0 (en) Compositions of matter
GB8431817D0 (en) Compositions of matter
GB8403362D0 (en) Compositions of matter
GB8421534D0 (en) Compositions of matter
GB8400690D0 (en) Compositions of matter
GB8405361D0 (en) Compositions of matter
GB8412494D0 (en) Compositions of matter
GB8409090D0 (en) Compositions of matter
GB8431375D0 (en) Compositions of matter
GB8422919D0 (en) Compositions of matter